

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DINGDANG HEALTH TECHNOLOGY GROUP LTD.

叮嚙健康科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 09886)

POSITIVE PROFIT ALERT – NARROWING OF LOSS

This announcement is made by Dingdang Health Technology Group Ltd. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2025 (the “**2025 Interim Period**”), the net loss for the 2025 Interim Period is expected to narrow by more than 40% compared to the net loss of approximately RMB89.8 million for the corresponding period in 2024. Such improvement was primarily attributable to an increase in gross profit resulting from an improved gross profit margin and a decrease in the general and administrative expenses during the 2025 Interim Period. The adjusted net loss^{Note} (non-IFRS measure) for the 2025 Interim Period is expected to be narrowed by more than RMB20 million compared to the adjusted net loss of approximately RMB26.4 million for the six months ended June 30, 2024.

Note: The adjusted net loss (non-IFRS measure) is provided by the Company as an additional financial indicator to supplement the consolidated financial statements prepared in accordance with IFRS. This measure is not required by, nor presented in accordance with, IFRS. According to the Company’s latest business operations and financial condition, the adjusted net loss (non-IFRS measure) for the 2025 Interim Period is calculated by taking the net loss for the 2025 Interim Period and adding back impairment of goodwill (if any) and other intangible assets (net of income tax effects) (if any), amortization of other intangible assets arising from acquisitions (net of income tax effects) and share-based payments expenses. The Company believes that the adjusted net loss (non-IFRS measure) provides useful information to assist the Company’s

management in understanding and evaluating the consolidated results of operations. However, the presentation of the adjusted net loss (non-IFRS measure) may not be comparable to other similarly titled indicators presented. The use of adjusted net loss (non-IFRS measure) has limitations as an analytical tool, and Shareholders and potential investors should not consider it in isolation from, or as a substitute for analysis of, results of operations or financial conditions of the Company as reported under IFRS.

The Company is still in the process of finalizing the interim results of the Group for the 2025 Interim Period. The information contained in this announcement is only a preliminary assessment by the Board based on the figures and information currently available, and is not audited or reviewed by the auditor or the audit committee of the Company and may differ with the actual interim results of the Group for the 2025 Interim Period. Shareholders and potential investors of the Company should refer to and carefully read the interim results announcement of the Company for the 2025 Interim Period, which is expected to be published in August 2025.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
DINGDANG HEALTH TECHNOLOGY GROUP LTD.
YANG WENLONG
Chairman

Hong Kong, August 1, 2025

As of the date of this announcement, the executive Directors are Mr. YANG Wenlong, Mr. XU Ning, Mr. YU Lei, Mr. YU Qinglong and Mr. YANG Yibin, the non-executive Director is Ms. LI Chuheng, and the independent non-executive Directors are Mr. ZHANG Shouchuan, Dr. FAN Zhenhong and Mr. JIANG Shan.